Polymorphisms in the IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies

Clinical and Experimental Immunology

Volumn 121, Issue 1, 2000, Pages 47-52

  Rider, Lisa G ^a,b,f   Artlett, C M ^c   Foster, C B ^d   Ahmed, A ^e   Neeman, T ^a   Chanock, S J ^d   Jimenez, S A ^c   Miller, F W ^a,b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e Specialty Laboratories   (United States)

^f CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Genetic risk factor; IL 1 receptors (genetics); Juvenile dermatomyositis; Myositis; Polymorphism

Indexed keywords

HLA DR ANTIGEN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; ALLELE; ARTICLE; AUTOIMMUNE DISEASE; DISEASE SEVERITY; ETHNOLOGY; FEMALE; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MYOPATHY; MYOSITIS; PATHOGENESIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; VARIABLE NUMBER OF TANDEM REPEAT;

ADOLESCENT; AUTOIMMUNE DISEASES; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MINISATELLITE REPEATS; MYOSITIS; POLYMORPHISM, GENETIC; PROGNOSIS; RECEPTORS, INTERLEUKIN-1; RISK FACTORS; SIALOGLYCOPROTEINS;

EID: 0033947203     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2000.01266.x     Document Type: Article

References (34)

1. Hurme M, Lahdenpohja N, Santtila S. Gene polymorphisms of interleukins 1 and 10 in infectious and autoimmune diseases. Ann Med 1998; 30:469-73.
2. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998; 16:27-55.
3. Tarlow JK, Blakemore AI, Lennard A, Solari R, Hughes HN, Steinkasserer A, Duff GW. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 1993; 91:403-4.
4. Blakemore AI, Tarlow JK, Cork MJ, Gordon C, Emery P, Duff GW. Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus. Arthritis Rheum 1994; 37:1380-5.
5. Bioque G, Crusius JB, Koutroubakis I, Bouma G, Kostense PJ, Meuwissen SG, Pena AS. Allelic polymorphism in IL-1 beta and IL-1 receptor antagonist (IL-1Ra) genes in inflammatory bowel disease. Clin Exp Immunol 1995; 102:379-83.
6. Tarlow JK, Clay FE, Cork MJ, Blakemore AI, McDonagh AJ, Messenger AG, Duff GW. Severity of alopecia areata is associated with a polymorphism in the interleukin-1 receptor antagonist gene. J Invest Dermatol 1994; 103:387-90.
7. Blakemore AI, Watson PF, Weetman AP, Duff GW. Association of Graves' disease with an allele of the interleukin-1 receptor antagonist gene. J Clin Endocrinol Metab 1995; 80:111-5.
8. Tarlow JK, Cork MJ, Clay FE et al. Association between interleukin-1 receptor antagonist (IL-1ra) gene polymorphism and early and late-onset psoriasis. Br J Dermatol 1997; 136:147-8.
9. Sciacca FL, Ferri C, Vandenbroeck K et al. Relevance of interleukin 1 receptor antagonist intron 2 polymorphism in Italian MS patients. Neurology 1999; 52:1896-8.
10. Cantagrel A, Navaux F, Loubet-Lescoulie P et al. Interleukin-1 beta, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms: relationship to occurrence and severity of rheumatoid arthritis. Arthritis Rheum 1999; 42:1093-100.
11. Muhlberg T, Kirchberger M, Spitzweg C, Herrmann F, Heberling HJ, Heufelder AE. Lack of association of Graves' disease with the A2 allele of the interleukin-1 receptor antagonist gene in a white European population. Eur J Endocrinol 1998; 138:686-90.
12. Louis E, Satsangi J, Roussomoustakaki M, Parkes M, Fanning G, Welsh K, Jewell D. Cytokine gene polymorphisms in inflammatory bowel disease. Gut 1996; 39:705-10.
13. Crowe WE, Bove KE, Levinson JE, Hilton PK. Clinical and pathogenetic implications of histopathology in childhood poly-dermatomyositis. Arthritis Rheum 1982; 25:126-39.
14. Pachman LM, Hayford JR, Chung A et al. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol 1998; 25:1198-204.
15. Reed AM, Pachman L, Ober C. Molecular genetic studies of major histocompatibility complex genes in children with juvenile dermatomyositis: increased risk associated with HLA-DQA1 *0501. Hum Immunol 1991; 32:235-40.
16. West JE, Reed AM. Analysis of HLA-DM polymorphism in juvenile dermatomyositis (JDM) patients. Hum Immunol 1999; 60:255-8.
17. Becker KG, Simon RM, Bailey-Wilson JE, Friedlin B, Biddison WE, McFarland HF, Trent JM. Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc Natl Acad Sci USA 1998; 95:9979-84.
18. Rider LG, Shamim E, Okada S et al. Genetic risk and protective factors for idiopathic inflammatory myopathy in Koreans and American whites: a tale of two loci. Arthritis Rheum 1999; 42:1285-90.
19. Gabay C, Gay-Croisier F, Roux-Lombard P, Meyer O, Maineti C, Guerne PA, Vischer T, Dayer JM. Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response. Arthritis Rheum 1994; 37:1744-51.
20. Prieur AM, Dayer A, Roux-Lombard P, Dayer JM. Levels of cytokine inhibitors: a possible marker of disease activity in childhood dermatomyositis and polymyositis. Clin Exp Rheumatol 1997; 15:211-4.
21. Lundberg I, Ulfgren AK, Nyberg P, Andersson U, Klareskog L. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997; 40:865-74.
22. Bohan A, Peter JB, Bowman RL, Pearson CM. . A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 1977; 56:255-86.
23. Lehrnbecher TL, Foster CB, Zhu S, Leitman SF, Goldin LR, Huppi K, Chanock SJ. Variant genotypes of the low affinity Fcγ receptors in two control populations and a comprehensive review of low affinity Fcγ receptor polymorphisms in control and disease populations. Bld 1999; 94:4220-32.
24. Westfall PH, Young SS. Resampling-based multiple testing: examples and methods for P-value adjustment. New York: John Wiley and Sons, 1993.
25. Foster CB, Lehrnbecher T, Mol F et al. Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease. J Clin Invest 1998; 102:2146-55.
26. Arnett FC, Targoff IN, Mimori T, Goldstein R, Warner NB, Reveille JD. Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arthritis Rheum 1996; 39:1507-18.
27. Remmers EF, Longman RE, Du Y, O'Hare A, Cannon GW, Griffiths MM, Wilder RL. A genome scan localizes five non-MHC loci controlling collagen-induced arthritis in rats. Nat Genet 1996; 14:82-85.
28. Fang XM, Schroder S, Hoeft A, Stuber F. Comparison of two polymorphisms of the interleukin-1 gene family: interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. Crit Care Med 1999; 27:1330-4.
29. Laurent C, Thibaut F, Ravassard P et al. Detection of two new polymorphic sites in the human interleukin-1 beta gene: lack of association with schizophrenia in a French population. Psychiatr Genet 1997; 7:103-5.
30. Bailly S, Israel N, Fay M, Gougerot-Pocidalo MA, Duff GW. An intronic polymorphic repeat sequence modulates interleukin-1 alpha gene regulation. Mol Immunol 1996; 33:999-1006.
31. McDowell TL, Symons JA, Ploski R, Forre O, Duff GW. A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1 alpha polymorphism. Arthritis Rheum 1995; 38:221-8.
32. Tjernstrom F, Hellmer G, Nived O, Truedsson L, Sturfelt G. Synergetic effect between interleukin-1 receptor antagonist allele (IL1RN*2) and MHC class II (DR17,DQ2) in determining susceptibility to systemic lupus erythematosus. Lupus 1999; 8:103-8.
33. Roussomoustakaki M, Satsangi J, Welsh K, Louis E, Fanning G, Targan S, Landers C, Jewell DP. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology 1997; 112:1845-53.
34. Wilkinson RJ, Patel P, Llewelyn M, Hirsch CS, Pasvol G, Snounou G, Davidson RN, Toosi Z. Influence of polymorphism in the genes for the interleukin (IL)-1 receptor antagonist and IL-1beta on tuberculosis. J Exp Med 1999; 189:1863-74.